Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-13

Clinical Trial Update: A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating XEN1101 versus placebo for focal onset seizures has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • XEN1101

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Focal Onset Seizures | Phase 3 | Status: COMPLETED